カテゴリー： Market Monitor Global, 世界, 医療/バイオ

DTaP＆Tdapワクチンの世界市場見通し2023年-2029年

◆英語タイトル：DTaP and Tdap Vaccines Market, Global Outlook and Forecast 2023-2029
	◆商品コード：MMG23LY8501 ◆発行会社（リサーチ会社）：Market Monitor Global ◆発行日：2023年7月（※2025年版があります。お問い合わせください。） ◆ページ数：77 ◆レポート形式：英語 / PDF ◆納品方法：Eメール（受注後2-3営業日） ◆調査対象地域：グローバル ◆産業分野：医薬品＆ヘルスケア

◆販売価格オプション（消費税別）

Single User（1名様閲覧用）	USD3,250 ⇒換算￥468,000	見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）	USD4,225 ⇒換算￥608,400	見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）	USD4,875 ⇒換算￥702,000	見積依頼/購入/質問フォーム

★Market Monitor Globalに受託調査の見積を依頼する

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

Global DTaP and Tdap Vaccines Market 調査レポートは次の情報を含め、グローバルにおけるのDTaP＆Tdapワクチン市場規模と予測を収録しています。・世界のDTaP＆Tdapワクチン市場：売上、2018年-2023年、2024年-2029年
・世界のDTaP＆Tdapワクチン市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界のDTaP＆Tdapワクチン市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。アメリカ市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「DTaP」セグメントは今後6年間、000%の年平均成長率で2029年までに000Mドルに成長すると予測されています。

DTaP＆Tdapワクチンのグローバル主要企業は、Sanofi Pasteur、 GlaxoSmithKline、 Protein Sciences Corporation、 Novartis AG、 Seqirus、 Merck Sharp & Dohme Corp、 Astellas Pharma US, Inc、 Pfizer Inc、 Johnson & Johnson、 Lanzhou Institute of Biological Products Co., Ltd、 AstraZeneca、 Emergent BioSolutions Incなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

マーケットモニターグローバル社は、DTaP＆Tdapワクチンのメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別マーケット分析】

世界のDTaP＆Tdapワクチン市場：タイプ別、2018年-2023年、2024年-2029年
世界のDTaP＆Tdapワクチン市場：タイプ別市場シェア、2022年
・DTaP、Td、Tdap

世界のDTaP＆Tdapワクチン市場：用途別、2018年-2023年、2024年-2029年
世界のDTaP＆Tdapワクチン市場：用途別市場シェア、2022年
・成人、小児

世界のDTaP＆Tdapワクチン市場：地域・国別、2018年-2023年、2024年-2029年
世界のDTaP＆Tdapワクチン市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競争分析】

また、当レポートは主要な参入企業の分析を提供します。
・主要企業におけるDTaP＆Tdapワクチンのグローバル売上、2018年-2023年
・主要企業におけるDTaP＆Tdapワクチンのグローバル売上シェア、2022年
・主要企業におけるDTaP＆Tdapワクチンのグローバル販売量、2018年-2023年
・主要企業におけるDTaP＆Tdapワクチンのグローバル販売量シェア、2022年

さらに、当レポートは主要企業の情報を提示します。
Sanofi Pasteur、 GlaxoSmithKline、 Protein Sciences Corporation、 Novartis AG、 Seqirus、 Merck Sharp & Dohme Corp、 Astellas Pharma US, Inc、 Pfizer Inc、 Johnson & Johnson、 Lanzhou Institute of Biological Products Co., Ltd、 AstraZeneca、 Emergent BioSolutions Inc

*************************************************************

・調査・分析レポートの概要
DTaP＆Tdapワクチン市場の定義
市場セグメント
世界のDTaP＆Tdapワクチン市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界のDTaP＆Tdapワクチン市場規模
世界のDTaP＆Tdapワクチン市場規模：2022年 VS 2029年
世界のDTaP＆Tdapワクチン市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでのDTaP＆Tdapワクチンの売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業のDTaP＆Tdapワクチン製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：DTaP、Td、Tdap
DTaP＆Tdapワクチンのタイプ別グローバル売上・予測

・用途別市場分析
用途区分：成人、小児
DTaP＆Tdapワクチンの用途別グローバル売上・予測

・地域別市場分析
地域別DTaP＆Tdapワクチン市場規模 2022年と2029年
地域別DTaP＆Tdapワクチン売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業の情報（企業概要、事業概要、主要製品、売上、ニュースなど）
Sanofi Pasteur、 GlaxoSmithKline、 Protein Sciences Corporation、 Novartis AG、 Seqirus、 Merck Sharp & Dohme Corp、 Astellas Pharma US, Inc、 Pfizer Inc、 Johnson & Johnson、 Lanzhou Institute of Biological Products Co., Ltd、 AstraZeneca、 Emergent BioSolutions Inc
...

Pertussis vaccine is used for whooping cough. This vaccine is available only in combination with other vaccines. Pertussis vaccination is recommended for all children, babies, teens, and pregnant women. Diphtheria, tetanus, and pertussis (DTaP) vaccines are given to children younger than seven years old, while tetanus, diphtheria, and pertussis (Tdap) vaccines are given to older children and adults. Childhood vaccination is one of the safest and cost-effective ways for pertussis-free environment. The World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC) recommend all children should be routinely vaccinated for pertussis. According to WHO in 2015, about 86% of infants received three doses of diphtheria-tetanus-pertussis (DTP3) vaccine worldwide to protect them against infectious diseases. In 2015, procurement of DTwP vaccine through UNICEF had reached 5.8 million doses for 18 countries and territories out of which four countries such as Egypt, Morocco, Uzbekistan, and Zimbabwe accounted for more than 80% of UNICEF’s total procurement.

Factors such as high birth rate, increase in number of geriatric population, government initiatives, growth in adoption of pertussis vaccination, and government insurance and reimbursement scenario are projected to drive the pertussis vaccine market globally. According to WHO in 2015, 126 countries had reached at least 90% coverage of diphtheria-tetanus-pertussis vaccine. On the other hand, factors such as vaccine injuries and adverse event are expected to hinder the growth of the pertussis vaccine market globally. In the U.S. in 2015, there had been 7 claims filed in the federal Vaccine Injury Compensation Program (VICP) for injuries and deaths following pertussis vaccination, including three deaths and four serious injuries.

The pertussis vaccine market has been segmented by product type, vaccine type, age group, end-user, and geography. In terms of product type, the pertussis vaccine market is classified into DTaP vaccine and Tdap vaccine. The DTaP vaccine segment includes products such as Daptacel, Infanrix, Kinrix, Pediarix, Pentacel, and Quaracel. The Tdap vaccine segment comprises products such as Boostrix and Adacel. In terms of vaccine type, the pertussis vaccine market is classified into whole-cell vaccine and acellular vaccine. The acellular vaccine segment is highly used owing to less side effect. The acellular vaccine is about 71%–85% effective, whereas whole-cell vaccine is about 78% effective. In terms of age group, the pertussis vaccine market is classified into adult and pediatric. In terms of end-user, the market is classified into hospitals, clinics, and vaccination centers. Geographically, the pertussis vaccine market is classified into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.

North America dominates the pertussis vaccine market due to growth in number of geriatric population and increase in pertussis death rate in the U.S, which drive the pertussis vaccine market. In 2014, according to the CDC, 28,660 cases of pertussis were reported in the U.S. The North America market is followed by the Europe and Asia Pacific markets. Asia Pacific is expected to grow at a higher rate due to rapid population growth, increase in adoption for vaccination, and growth in prevalence of infectious disease. These factors are expected to fuel the pertussis vaccine market. In the Asia Pacific region, Thailand accounts for 99% in pertussis vaccine coverage, followed by Japan and China with 98% and 97%, respectively. Developing countries such as Brazil, South Africa, and Mexico are estimated to create good opportunity for the pertussis vaccine market growth attributing to rise in number of government and private health care insurance coverage, increase in health care expenditure, and growth in awareness among people.
This report aims to provide a comprehensive presentation of the global market for DTaP and Tdap Vaccines, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding DTaP and Tdap Vaccines. This report contains market size and forecasts of DTaP and Tdap Vaccines in global, including the following market information:
Global DTaP and Tdap Vaccines Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global DTaP and Tdap Vaccines Market Sales, 2018-2023, 2024-2029, (K Units)
Global top five DTaP and Tdap Vaccines companies in 2022 (%)
The global DTaP and Tdap Vaccines market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
DTaP Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of DTaP and Tdap Vaccines include Sanofi Pasteur, GlaxoSmithKline, Protein Sciences Corporation, Novartis AG, Seqirus, Merck Sharp & Dohme Corp, Astellas Pharma US, Inc, Pfizer Inc and Johnson & Johnson, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the DTaP and Tdap Vaccines manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global DTaP and Tdap Vaccines Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global DTaP and Tdap Vaccines Market Segment Percentages, by Type, 2022 (%)
DTaP
Td
Tdap
Global DTaP and Tdap Vaccines Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global DTaP and Tdap Vaccines Market Segment Percentages, by Application, 2022 (%)
Adult
Pediatric
Global DTaP and Tdap Vaccines Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global DTaP and Tdap Vaccines Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies DTaP and Tdap Vaccines revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies DTaP and Tdap Vaccines revenues share in global market, 2022 (%)
Key companies DTaP and Tdap Vaccines sales in global market, 2018-2023 (Estimated), (K Units)
Key companies DTaP and Tdap Vaccines sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Sanofi Pasteur
GlaxoSmithKline
Protein Sciences Corporation
Novartis AG
Seqirus
Merck Sharp & Dohme Corp
Astellas Pharma US, Inc
Pfizer Inc
Johnson & Johnson
Lanzhou Institute of Biological Products Co., Ltd
AstraZeneca
Emergent BioSolutions Inc
Outline of Major Chapters:
Chapter 1: Introduces the definition of DTaP and Tdap Vaccines, market overview.
Chapter 2: Global DTaP and Tdap Vaccines market size in revenue and volume.
Chapter 3: Detailed analysis of DTaP and Tdap Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of DTaP and Tdap Vaccines in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global DTaP and Tdap Vaccines capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.

❖ レポートの目次 ❖

1 Introduction to Research & Analysis Reports
1.1 DTaP and Tdap Vaccines Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global DTaP and Tdap Vaccines Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global DTaP and Tdap Vaccines Overall Market Size
2.1 Global DTaP and Tdap Vaccines Market Size: 2022 VS 2029
2.2 Global DTaP and Tdap Vaccines Revenue, Prospects & Forecasts: 2018-2029
2.3 Global DTaP and Tdap Vaccines Sales: 2018-2029
3 Company Landscape
3.1 Top DTaP and Tdap Vaccines Players in Global Market
3.2 Top Global DTaP and Tdap Vaccines Companies Ranked by Revenue
3.3 Global DTaP and Tdap Vaccines Revenue by Companies
3.4 Global DTaP and Tdap Vaccines Sales by Companies
3.5 Global DTaP and Tdap Vaccines Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 DTaP and Tdap Vaccines Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers DTaP and Tdap Vaccines Product Type
3.8 Tier 1, Tier 2 and Tier 3 DTaP and Tdap Vaccines Players in Global Market
3.8.1 List of Global Tier 1 DTaP and Tdap Vaccines Companies
3.8.2 List of Global Tier 2 and Tier 3 DTaP and Tdap Vaccines Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global DTaP and Tdap Vaccines Market Size Markets, 2022 & 2029
4.1.2 DTaP
4.1.3 Td
4.1.4 Tdap
4.2 By Type – Global DTaP and Tdap Vaccines Revenue & Forecasts
4.2.1 By Type – Global DTaP and Tdap Vaccines Revenue, 2018-2023
4.2.2 By Type – Global DTaP and Tdap Vaccines Revenue, 2024-2029
4.2.3 By Type – Global DTaP and Tdap Vaccines Revenue Market Share, 2018-2029
4.3 By Type – Global DTaP and Tdap Vaccines Sales & Forecasts
4.3.1 By Type – Global DTaP and Tdap Vaccines Sales, 2018-2023
4.3.2 By Type – Global DTaP and Tdap Vaccines Sales, 2024-2029
4.3.3 By Type – Global DTaP and Tdap Vaccines Sales Market Share, 2018-2029
4.4 By Type – Global DTaP and Tdap Vaccines Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global DTaP and Tdap Vaccines Market Size, 2022 & 2029
5.1.2 Adult
5.1.3 Pediatric
5.2 By Application – Global DTaP and Tdap Vaccines Revenue & Forecasts
5.2.1 By Application – Global DTaP and Tdap Vaccines Revenue, 2018-2023
5.2.2 By Application – Global DTaP and Tdap Vaccines Revenue, 2024-2029
5.2.3 By Application – Global DTaP and Tdap Vaccines Revenue Market Share, 2018-2029
5.3 By Application – Global DTaP and Tdap Vaccines Sales & Forecasts
5.3.1 By Application – Global DTaP and Tdap Vaccines Sales, 2018-2023
5.3.2 By Application – Global DTaP and Tdap Vaccines Sales, 2024-2029
5.3.3 By Application – Global DTaP and Tdap Vaccines Sales Market Share, 2018-2029
5.4 By Application – Global DTaP and Tdap Vaccines Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global DTaP and Tdap Vaccines Market Size, 2022 & 2029
6.2 By Region – Global DTaP and Tdap Vaccines Revenue & Forecasts
6.2.1 By Region – Global DTaP and Tdap Vaccines Revenue, 2018-2023
6.2.2 By Region – Global DTaP and Tdap Vaccines Revenue, 2024-2029
6.2.3 By Region – Global DTaP and Tdap Vaccines Revenue Market Share, 2018-2029
6.3 By Region – Global DTaP and Tdap Vaccines Sales & Forecasts
6.3.1 By Region – Global DTaP and Tdap Vaccines Sales, 2018-2023
6.3.2 By Region – Global DTaP and Tdap Vaccines Sales, 2024-2029
6.3.3 By Region – Global DTaP and Tdap Vaccines Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America DTaP and Tdap Vaccines Revenue, 2018-2029
6.4.2 By Country – North America DTaP and Tdap Vaccines Sales, 2018-2029
6.4.3 US DTaP and Tdap Vaccines Market Size, 2018-2029
6.4.4 Canada DTaP and Tdap Vaccines Market Size, 2018-2029
6.4.5 Mexico DTaP and Tdap Vaccines Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe DTaP and Tdap Vaccines Revenue, 2018-2029
6.5.2 By Country – Europe DTaP and Tdap Vaccines Sales, 2018-2029
6.5.3 Germany DTaP and Tdap Vaccines Market Size, 2018-2029
6.5.4 France DTaP and Tdap Vaccines Market Size, 2018-2029
6.5.5 U.K. DTaP and Tdap Vaccines Market Size, 2018-2029
6.5.6 Italy DTaP and Tdap Vaccines Market Size, 2018-2029
6.5.7 Russia DTaP and Tdap Vaccines Market Size, 2018-2029
6.5.8 Nordic Countries DTaP and Tdap Vaccines Market Size, 2018-2029
6.5.9 Benelux DTaP and Tdap Vaccines Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia DTaP and Tdap Vaccines Revenue, 2018-2029
6.6.2 By Region – Asia DTaP and Tdap Vaccines Sales, 2018-2029
6.6.3 China DTaP and Tdap Vaccines Market Size, 2018-2029
6.6.4 Japan DTaP and Tdap Vaccines Market Size, 2018-2029
6.6.5 South Korea DTaP and Tdap Vaccines Market Size, 2018-2029
6.6.6 Southeast Asia DTaP and Tdap Vaccines Market Size, 2018-2029
6.6.7 India DTaP and Tdap Vaccines Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America DTaP and Tdap Vaccines Revenue, 2018-2029
6.7.2 By Country – South America DTaP and Tdap Vaccines Sales, 2018-2029
6.7.3 Brazil DTaP and Tdap Vaccines Market Size, 2018-2029
6.7.4 Argentina DTaP and Tdap Vaccines Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa DTaP and Tdap Vaccines Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa DTaP and Tdap Vaccines Sales, 2018-2029
6.8.3 Turkey DTaP and Tdap Vaccines Market Size, 2018-2029
6.8.4 Israel DTaP and Tdap Vaccines Market Size, 2018-2029
6.8.5 Saudi Arabia DTaP and Tdap Vaccines Market Size, 2018-2029
6.8.6 UAE DTaP and Tdap Vaccines Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Sanofi Pasteur
7.1.1 Sanofi Pasteur Company Summary
7.1.2 Sanofi Pasteur Business Overview
7.1.3 Sanofi Pasteur DTaP and Tdap Vaccines Major Product Offerings
7.1.4 Sanofi Pasteur DTaP and Tdap Vaccines Sales and Revenue in Global (2018-2023)
7.1.5 Sanofi Pasteur Key News & Latest Developments
7.2 GlaxoSmithKline
7.2.1 GlaxoSmithKline Company Summary
7.2.2 GlaxoSmithKline Business Overview
7.2.3 GlaxoSmithKline DTaP and Tdap Vaccines Major Product Offerings
7.2.4 GlaxoSmithKline DTaP and Tdap Vaccines Sales and Revenue in Global (2018-2023)
7.2.5 GlaxoSmithKline Key News & Latest Developments
7.3 Protein Sciences Corporation
7.3.1 Protein Sciences Corporation Company Summary
7.3.2 Protein Sciences Corporation Business Overview
7.3.3 Protein Sciences Corporation DTaP and Tdap Vaccines Major Product Offerings
7.3.4 Protein Sciences Corporation DTaP and Tdap Vaccines Sales and Revenue in Global (2018-2023)
7.3.5 Protein Sciences Corporation Key News & Latest Developments
7.4 Novartis AG
7.4.1 Novartis AG Company Summary
7.4.2 Novartis AG Business Overview
7.4.3 Novartis AG DTaP and Tdap Vaccines Major Product Offerings
7.4.4 Novartis AG DTaP and Tdap Vaccines Sales and Revenue in Global (2018-2023)
7.4.5 Novartis AG Key News & Latest Developments
7.5 Seqirus
7.5.1 Seqirus Company Summary
7.5.2 Seqirus Business Overview
7.5.3 Seqirus DTaP and Tdap Vaccines Major Product Offerings
7.5.4 Seqirus DTaP and Tdap Vaccines Sales and Revenue in Global (2018-2023)
7.5.5 Seqirus Key News & Latest Developments
7.6 Merck Sharp & Dohme Corp
7.6.1 Merck Sharp & Dohme Corp Company Summary
7.6.2 Merck Sharp & Dohme Corp Business Overview
7.6.3 Merck Sharp & Dohme Corp DTaP and Tdap Vaccines Major Product Offerings
7.6.4 Merck Sharp & Dohme Corp DTaP and Tdap Vaccines Sales and Revenue in Global (2018-2023)
7.6.5 Merck Sharp & Dohme Corp Key News & Latest Developments
7.7 Astellas Pharma US, Inc
7.7.1 Astellas Pharma US, Inc Company Summary
7.7.2 Astellas Pharma US, Inc Business Overview
7.7.3 Astellas Pharma US, Inc DTaP and Tdap Vaccines Major Product Offerings
7.7.4 Astellas Pharma US, Inc DTaP and Tdap Vaccines Sales and Revenue in Global (2018-2023)
7.7.5 Astellas Pharma US, Inc Key News & Latest Developments
7.8 Pfizer Inc
7.8.1 Pfizer Inc Company Summary
7.8.2 Pfizer Inc Business Overview
7.8.3 Pfizer Inc DTaP and Tdap Vaccines Major Product Offerings
7.8.4 Pfizer Inc DTaP and Tdap Vaccines Sales and Revenue in Global (2018-2023)
7.8.5 Pfizer Inc Key News & Latest Developments
7.9 Johnson & Johnson
7.9.1 Johnson & Johnson Company Summary
7.9.2 Johnson & Johnson Business Overview
7.9.3 Johnson & Johnson DTaP and Tdap Vaccines Major Product Offerings
7.9.4 Johnson & Johnson DTaP and Tdap Vaccines Sales and Revenue in Global (2018-2023)
7.9.5 Johnson & Johnson Key News & Latest Developments
7.10 Lanzhou Institute of Biological Products Co., Ltd
7.10.1 Lanzhou Institute of Biological Products Co., Ltd Company Summary
7.10.2 Lanzhou Institute of Biological Products Co., Ltd Business Overview
7.10.3 Lanzhou Institute of Biological Products Co., Ltd DTaP and Tdap Vaccines Major Product Offerings
7.10.4 Lanzhou Institute of Biological Products Co., Ltd DTaP and Tdap Vaccines Sales and Revenue in Global (2018-2023)
7.10.5 Lanzhou Institute of Biological Products Co., Ltd Key News & Latest Developments
7.11 AstraZeneca
7.11.1 AstraZeneca Company Summary
7.11.2 AstraZeneca DTaP and Tdap Vaccines Business Overview
7.11.3 AstraZeneca DTaP and Tdap Vaccines Major Product Offerings
7.11.4 AstraZeneca DTaP and Tdap Vaccines Sales and Revenue in Global (2018-2023)
7.11.5 AstraZeneca Key News & Latest Developments
7.12 Emergent BioSolutions Inc
7.12.1 Emergent BioSolutions Inc Company Summary
7.12.2 Emergent BioSolutions Inc DTaP and Tdap Vaccines Business Overview
7.12.3 Emergent BioSolutions Inc DTaP and Tdap Vaccines Major Product Offerings
7.12.4 Emergent BioSolutions Inc DTaP and Tdap Vaccines Sales and Revenue in Global (2018-2023)
7.12.5 Emergent BioSolutions Inc Key News & Latest Developments
8 Global DTaP and Tdap Vaccines Production Capacity, Analysis
8.1 Global DTaP and Tdap Vaccines Production Capacity, 2018-2029
8.2 DTaP and Tdap Vaccines Production Capacity of Key Manufacturers in Global Market
8.3 Global DTaP and Tdap Vaccines Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 DTaP and Tdap Vaccines Supply Chain Analysis
10.1 DTaP and Tdap Vaccines Industry Value Chain
10.2 DTaP and Tdap Vaccines Upstream Market
10.3 DTaP and Tdap Vaccines Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 DTaP and Tdap Vaccines Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer

List of Tables
Table 1. Key Players of DTaP and Tdap Vaccines in Global Market
Table 2. Top DTaP and Tdap Vaccines Players in Global Market, Ranking by Revenue (2022)
Table 3. Global DTaP and Tdap Vaccines Revenue by Companies, (US$, Mn), 2018-2023
Table 4. Global DTaP and Tdap Vaccines Revenue Share by Companies, 2018-2023
Table 5. Global DTaP and Tdap Vaccines Sales by Companies, (K Units), 2018-2023
Table 6. Global DTaP and Tdap Vaccines Sales Share by Companies, 2018-2023
Table 7. Key Manufacturers DTaP and Tdap Vaccines Price (2018-2023) & (USD/Unit)
Table 8. Global Manufacturers DTaP and Tdap Vaccines Product Type
Table 9. List of Global Tier 1 DTaP and Tdap Vaccines Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 DTaP and Tdap Vaccines Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type – Global DTaP and Tdap Vaccines Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Global DTaP and Tdap Vaccines Revenue (US$, Mn), 2018-2023
Table 13. By Type - Global DTaP and Tdap Vaccines Revenue (US$, Mn), 2024-2029
Table 14. By Type - Global DTaP and Tdap Vaccines Sales (K Units), 2018-2023
Table 15. By Type - Global DTaP and Tdap Vaccines Sales (K Units), 2024-2029
Table 16. By Application – Global DTaP and Tdap Vaccines Revenue, (US$, Mn), 2022 & 2029
Table 17. By Application - Global DTaP and Tdap Vaccines Revenue (US$, Mn), 2018-2023
Table 18. By Application - Global DTaP and Tdap Vaccines Revenue (US$, Mn), 2024-2029
Table 19. By Application - Global DTaP and Tdap Vaccines Sales (K Units), 2018-2023
Table 20. By Application - Global DTaP and Tdap Vaccines Sales (K Units), 2024-2029
Table 21. By Region – Global DTaP and Tdap Vaccines Revenue, (US$, Mn), 2022 VS 2029
Table 22. By Region - Global DTaP and Tdap Vaccines Revenue (US$, Mn), 2018-2023
Table 23. By Region - Global DTaP and Tdap Vaccines Revenue (US$, Mn), 2024-2029
Table 24. By Region - Global DTaP and Tdap Vaccines Sales (K Units), 2018-2023
Table 25. By Region - Global DTaP and Tdap Vaccines Sales (K Units), 2024-2029
Table 26. By Country - North America DTaP and Tdap Vaccines Revenue, (US$, Mn), 2018-2023
Table 27. By Country - North America DTaP and Tdap Vaccines Revenue, (US$, Mn), 2024-2029
Table 28. By Country - North America DTaP and Tdap Vaccines Sales, (K Units), 2018-2023
Table 29. By Country - North America DTaP and Tdap Vaccines Sales, (K Units), 2024-2029
Table 30. By Country - Europe DTaP and Tdap Vaccines Revenue, (US$, Mn), 2018-2023
Table 31. By Country - Europe DTaP and Tdap Vaccines Revenue, (US$, Mn), 2024-2029
Table 32. By Country - Europe DTaP and Tdap Vaccines Sales, (K Units), 2018-2023
Table 33. By Country - Europe DTaP and Tdap Vaccines Sales, (K Units), 2024-2029
Table 34. By Region - Asia DTaP and Tdap Vaccines Revenue, (US$, Mn), 2018-2023
Table 35. By Region - Asia DTaP and Tdap Vaccines Revenue, (US$, Mn), 2024-2029
Table 36. By Region - Asia DTaP and Tdap Vaccines Sales, (K Units), 2018-2023
Table 37. By Region - Asia DTaP and Tdap Vaccines Sales, (K Units), 2024-2029
Table 38. By Country - South America DTaP and Tdap Vaccines Revenue, (US$, Mn), 2018-2023
Table 39. By Country - South America DTaP and Tdap Vaccines Revenue, (US$, Mn), 2024-2029
Table 40. By Country - South America DTaP and Tdap Vaccines Sales, (K Units), 2018-2023
Table 41. By Country - South America DTaP and Tdap Vaccines Sales, (K Units), 2024-2029
Table 42. By Country - Middle East & Africa DTaP and Tdap Vaccines Revenue, (US$, Mn), 2018-2023
Table 43. By Country - Middle East & Africa DTaP and Tdap Vaccines Revenue, (US$, Mn), 2024-2029
Table 44. By Country - Middle East & Africa DTaP and Tdap Vaccines Sales, (K Units), 2018-2023
Table 45. By Country - Middle East & Africa DTaP and Tdap Vaccines Sales, (K Units), 2024-2029
Table 46. Sanofi Pasteur Company Summary
Table 47. Sanofi Pasteur DTaP and Tdap Vaccines Product Offerings
Table 48. Sanofi Pasteur DTaP and Tdap Vaccines Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 49. Sanofi Pasteur Key News & Latest Developments
Table 50. GlaxoSmithKline Company Summary
Table 51. GlaxoSmithKline DTaP and Tdap Vaccines Product Offerings
Table 52. GlaxoSmithKline DTaP and Tdap Vaccines Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 53. GlaxoSmithKline Key News & Latest Developments
Table 54. Protein Sciences Corporation Company Summary
Table 55. Protein Sciences Corporation DTaP and Tdap Vaccines Product Offerings
Table 56. Protein Sciences Corporation DTaP and Tdap Vaccines Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 57. Protein Sciences Corporation Key News & Latest Developments
Table 58. Novartis AG Company Summary
Table 59. Novartis AG DTaP and Tdap Vaccines Product Offerings
Table 60. Novartis AG DTaP and Tdap Vaccines Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 61. Novartis AG Key News & Latest Developments
Table 62. Seqirus Company Summary
Table 63. Seqirus DTaP and Tdap Vaccines Product Offerings
Table 64. Seqirus DTaP and Tdap Vaccines Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 65. Seqirus Key News & Latest Developments
Table 66. Merck Sharp & Dohme Corp Company Summary
Table 67. Merck Sharp & Dohme Corp DTaP and Tdap Vaccines Product Offerings
Table 68. Merck Sharp & Dohme Corp DTaP and Tdap Vaccines Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 69. Merck Sharp & Dohme Corp Key News & Latest Developments
Table 70. Astellas Pharma US, Inc Company Summary
Table 71. Astellas Pharma US, Inc DTaP and Tdap Vaccines Product Offerings
Table 72. Astellas Pharma US, Inc DTaP and Tdap Vaccines Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 73. Astellas Pharma US, Inc Key News & Latest Developments
Table 74. Pfizer Inc Company Summary
Table 75. Pfizer Inc DTaP and Tdap Vaccines Product Offerings
Table 76. Pfizer Inc DTaP and Tdap Vaccines Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 77. Pfizer Inc Key News & Latest Developments
Table 78. Johnson & Johnson Company Summary
Table 79. Johnson & Johnson DTaP and Tdap Vaccines Product Offerings
Table 80. Johnson & Johnson DTaP and Tdap Vaccines Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 81. Johnson & Johnson Key News & Latest Developments
Table 82. Lanzhou Institute of Biological Products Co., Ltd Company Summary
Table 83. Lanzhou Institute of Biological Products Co., Ltd DTaP and Tdap Vaccines Product Offerings
Table 84. Lanzhou Institute of Biological Products Co., Ltd DTaP and Tdap Vaccines Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 85. Lanzhou Institute of Biological Products Co., Ltd Key News & Latest Developments
Table 86. AstraZeneca Company Summary
Table 87. AstraZeneca DTaP and Tdap Vaccines Product Offerings
Table 88. AstraZeneca DTaP and Tdap Vaccines Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 89. AstraZeneca Key News & Latest Developments
Table 90. Emergent BioSolutions Inc Company Summary
Table 91. Emergent BioSolutions Inc DTaP and Tdap Vaccines Product Offerings
Table 92. Emergent BioSolutions Inc DTaP and Tdap Vaccines Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 93. Emergent BioSolutions Inc Key News & Latest Developments
Table 94. DTaP and Tdap Vaccines Production Capacity (K Units) of Key Manufacturers in Global Market, 2021-2023 (K Units)
Table 95. Global DTaP and Tdap Vaccines Capacity Market Share of Key Manufacturers, 2021-2023
Table 96. Global DTaP and Tdap Vaccines Production by Region, 2018-2023 (K Units)
Table 97. Global DTaP and Tdap Vaccines Production by Region, 2024-2029 (K Units)
Table 98. DTaP and Tdap Vaccines Market Opportunities & Trends in Global Market
Table 99. DTaP and Tdap Vaccines Market Drivers in Global Market
Table 100. DTaP and Tdap Vaccines Market Restraints in Global Market
Table 101. DTaP and Tdap Vaccines Raw Materials
Table 102. DTaP and Tdap Vaccines Raw Materials Suppliers in Global Market
Table 103. Typical DTaP and Tdap Vaccines Downstream
Table 104. DTaP and Tdap Vaccines Downstream Clients in Global Market
Table 105. DTaP and Tdap Vaccines Distributors and Sales Agents in Global Market
List of Figures
Figure 1. DTaP and Tdap Vaccines Segment by Type in 2022
Figure 2. DTaP and Tdap Vaccines Segment by Application in 2022
Figure 3. Global DTaP and Tdap Vaccines Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global DTaP and Tdap Vaccines Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global DTaP and Tdap Vaccines Revenue, 2018-2029 (US$, Mn)
Figure 7. DTaP and Tdap Vaccines Sales in Global Market: 2018-2029 (K Units)
Figure 8. The Top 3 and 5 Players Market Share by DTaP and Tdap Vaccines Revenue in 2022
Figure 9. By Type - Global DTaP and Tdap Vaccines Revenue, (US$, Mn), 2022 & 2029
Figure 10. By Type - Global DTaP and Tdap Vaccines Revenue Market Share, 2018-2029
Figure 11. By Type - Global DTaP and Tdap Vaccines Sales Market Share, 2018-2029
Figure 12. By Type - Global DTaP and Tdap Vaccines Price (USD/Unit), 2018-2029
Figure 13. By Application - Global DTaP and Tdap Vaccines Revenue, (US$, Mn), 2022 & 2029
Figure 14. By Application - Global DTaP and Tdap Vaccines Revenue Market Share, 2018-2029
Figure 15. By Application - Global DTaP and Tdap Vaccines Sales Market Share, 2018-2029
Figure 16. By Application - Global DTaP and Tdap Vaccines Price (USD/Unit), 2018-2029
Figure 17. By Region - Global DTaP and Tdap Vaccines Revenue, (US$, Mn), 2022 & 2029
Figure 18. By Region - Global DTaP and Tdap Vaccines Revenue Market Share, 2018 VS 2022 VS 2029
Figure 19. By Region - Global DTaP and Tdap Vaccines Revenue Market Share, 2018-2029
Figure 20. By Region - Global DTaP and Tdap Vaccines Sales Market Share, 2018-2029
Figure 21. By Country - North America DTaP and Tdap Vaccines Revenue Market Share, 2018-2029
Figure 22. By Country - North America DTaP and Tdap Vaccines Sales Market Share, 2018-2029
Figure 23. US DTaP and Tdap Vaccines Revenue, (US$, Mn), 2018-2029
Figure 24. Canada DTaP and Tdap Vaccines Revenue, (US$, Mn), 2018-2029
Figure 25. Mexico DTaP and Tdap Vaccines Revenue, (US$, Mn), 2018-2029
Figure 26. By Country - Europe DTaP and Tdap Vaccines Revenue Market Share, 2018-2029
Figure 27. By Country - Europe DTaP and Tdap Vaccines Sales Market Share, 2018-2029
Figure 28. Germany DTaP and Tdap Vaccines Revenue, (US$, Mn), 2018-2029
Figure 29. France DTaP and Tdap Vaccines Revenue, (US$, Mn), 2018-2029
Figure 30. U.K. DTaP and Tdap Vaccines Revenue, (US$, Mn), 2018-2029
Figure 31. Italy DTaP and Tdap Vaccines Revenue, (US$, Mn), 2018-2029
Figure 32. Russia DTaP and Tdap Vaccines Revenue, (US$, Mn), 2018-2029
Figure 33. Nordic Countries DTaP and Tdap Vaccines Revenue, (US$, Mn), 2018-2029
Figure 34. Benelux DTaP and Tdap Vaccines Revenue, (US$, Mn), 2018-2029
Figure 35. By Region - Asia DTaP and Tdap Vaccines Revenue Market Share, 2018-2029
Figure 36. By Region - Asia DTaP and Tdap Vaccines Sales Market Share, 2018-2029
Figure 37. China DTaP and Tdap Vaccines Revenue, (US$, Mn), 2018-2029
Figure 38. Japan DTaP and Tdap Vaccines Revenue, (US$, Mn), 2018-2029
Figure 39. South Korea DTaP and Tdap Vaccines Revenue, (US$, Mn), 2018-2029
Figure 40. Southeast Asia DTaP and Tdap Vaccines Revenue, (US$, Mn), 2018-2029
Figure 41. India DTaP and Tdap Vaccines Revenue, (US$, Mn), 2018-2029
Figure 42. By Country - South America DTaP and Tdap Vaccines Revenue Market Share, 2018-2029
Figure 43. By Country - South America DTaP and Tdap Vaccines Sales Market Share, 2018-2029
Figure 44. Brazil DTaP and Tdap Vaccines Revenue, (US$, Mn), 2018-2029
Figure 45. Argentina DTaP and Tdap Vaccines Revenue, (US$, Mn), 2018-2029
Figure 46. By Country - Middle East & Africa DTaP and Tdap Vaccines Revenue Market Share, 2018-2029
Figure 47. By Country - Middle East & Africa DTaP and Tdap Vaccines Sales Market Share, 2018-2029
Figure 48. Turkey DTaP and Tdap Vaccines Revenue, (US$, Mn), 2018-2029
Figure 49. Israel DTaP and Tdap Vaccines Revenue, (US$, Mn), 2018-2029
Figure 50. Saudi Arabia DTaP and Tdap Vaccines Revenue, (US$, Mn), 2018-2029
Figure 51. UAE DTaP and Tdap Vaccines Revenue, (US$, Mn), 2018-2029
Figure 52. Global DTaP and Tdap Vaccines Production Capacity (K Units), 2018-2029
Figure 53. The Percentage of Production DTaP and Tdap Vaccines by Region, 2022 VS 2029
Figure 54. DTaP and Tdap Vaccines Industry Value Chain
Figure 55. Marketing Channels

※参考情報

DTaPおよびTdapワクチンは、ジフテリア、破傷風、百日咳を予防するための重要なワクチンです。これらのワクチンは特に子どもや大人に対して、これらの病気による重大な健康リスクから守るために開発されました。

まず、DTaPワクチンは、小児期に接種されるワクチンで、ジフテリア（D）、破傷風（T）、百日咳（aP）の3つの病気を予防します。通常、子どもは生後2ヶ月から接種を開始し、数回の接種が推奨されています。このワクチンの接種スケジュールは、通常3回の初回接種とその後のブースター接種が行われ、完全な免疫を形成することを目指しています。DTaPは細胞性よりも不活化された成分を多く含むため、免疫反応がより穏やかであり、副反応のリスクも低くなっています。

一方、Tdapワクチンは、成人や思春期の若者に対して推奨されるワクチンで、ジフテリア、破傷風、そして成人に特に重要な百日咳を予防します。Tdapは、ドーズとしてのジフテリアと破傷風の含有量が低く、主に百日咳の防止を目的として設計されています。このため、既にDTaPを接種している人々が成人期に再度免疫を強化するために接種することが非常に重要です。

DTaPとTdapの主な目的は、感染症を予防することだけではありません。特に百日咳は、特に新生児や幼児に対して重篤な合併症を引き起こす可能性があるため、周囲の大人が予防接種を受けていることが新生児を守るためにも重要です。これは「間接免疫」と呼ばれる概念であり、集団免疫として知られる、周囲の多くの人々が免疫を持つことで、病気の広がりを抑制する仕組みです。

さらに、DTaPおよびTdapワクチンの開発には、様々な技術が導入されています。ワクチンの製造プロセスでは、多くの研究が行われ、いくつかの異なる技術が使用されています。特にモノクローナル抗体の技術や遺伝子工学の利用が進み、効果的で安全性の高いワクチンが作られるようになっています。これにより、副作用を軽減し、効率的に免疫を形成できるようなワクチンの改良がなされてきました。

DTaPおよびTdapワクチンは通常、筋肉注射として接種されます。通常、子供に対しては上腕部に接種し、成人や思春期の若者でも同様の部位に接種されます。接種後の副反応としては、注射部位の痛み、腫れ、軽度の発熱などがありますが、ほとんどの場合は軽微であり、数日以内に自然に回復します。ワクチン接種により、期待される効果は高く、これらの疾患による重篤な症状を防ぐことができます。

他のワクチンと同様に、DTaPおよびTdapワクチンに関しても、接種に際しては医療従事者との相談が重要です。アレルギーや過去の副反応の有無、既往歴などを考慮し、適切な判断が必要です。特に妊婦や特定の疾患を持つ人々に関しては、接種のタイミングや種類について医師の指導を仰ぐことが大切です。

近年の健康政策では、ワクチン接種の重要性が再認識されており、特に百日咳の流行が報告される中で、大人のワクチン接種が非常に重要視されています。ワクチン接種率の向上は、未接種の新生児や幼児を守るだけでなく、社会全体の健康維持にも寄与します。ワクチンに対する疑念や誤解が広がる現代において、科学的根拠に基づいた情報提供が求められています。

そのため、教育や啓発活動が各地で実施されており、ワクチンの利点や必要性を一般の人々に理解してもらう努力が続けられています。現代社会においては、ワクチン接種を通じて病気から自分自身を守るだけでなく、周囲の人々を守るという責任感を持つことがますます重要になっています。特に、ジフテリアや破傷風、百日咳といった疾患は一度は減少したように見えましたが、近年再び流行の兆候が見える中で、適切な予防策としてのワクチンの役割が高まっています。

まとめとして、DTaPおよびTdapワクチンは、デフテリア、破傷風、百日咳の予防に非常に重要であり、接種が推奨されるワクチンです。ワクチンによる免疫は健康を守るための基本であり、個人および公共の健康の維持に不可欠です。医療従事者との相談のもと、適切なワクチン接種を受けることで、自身の健康を守り、社会全体の健康促進に寄与していきましょう。このような取り組みが、今後ますます重要視されていくでしょう。

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ DTaP＆Tdapワクチンの世界市場見通し2023年-2029年(DTaP and Tdap Vaccines Market, Global Outlook and Forecast 2023-2029)]についてメールでお問い合わせはこちらでお願いします。

GlobalResearch.jp

DTaP＆Tdapワクチンの世界市場見通し2023年-2029年

グローバル市場調査/マーケットリサーチ会社：レポート販売と委託調査サービス提供 www.GlobalResearch.jp